Get the Stockscreener App
83.40
0.51%
0.60
Spruce Biosciences Inc stock is traded at $83.40, with a volume of 8,401.
It is up +0.51% in the last 24 hours and down -23.25% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$84.00
Open:
$83.4
24h Volume:
8,401
Relative Volume:
0.02
Market Cap:
$90.37M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-88.72
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
+7.23%
1M Performance:
-23.25%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$82.88
$85.31
1-Week Range:
$77.48
$87.11
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
84.43 | 89.91M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.75 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.30 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.37 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
848.83 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
178.20 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Equities Analysts Offer Predictions for SPRB FY2025 Earnings - MarketBeat
Spruce Biosciences initiated with an Outperform at Oppenheimer - Yahoo Finance
Oppenheimer Initiates Coverage on SPRB with "Outperform" Rating - GuruFocus
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Yahoo Finance
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength - TradingView — Track All Markets
Oppenheimer initiates coverage on Spruce Biosciences stock with Outperform rating - Investing.com Nigeria
Oppenheimer Initiates Coverage of Spruce Biosciences (SPRB) with Outperform Recommendation - Nasdaq
Spruce Biosciences stock rating resumed at Buy by H.C. Wainwright - Investing.com Nigeria
HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB) - MarketBeat
SPRB Stock: HC Wainwright & Co. Initiates Coverage with Buy Rati - GuruFocus
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences CEO reports RSU vesting and option repricing | SPRB SEC FilingForm 4 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail
Spruce Biosciences (SPRB) adjusts director option exercise prices to $104.13 - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) reprices stock options after reverse split - Stock Titan
Spruce Biosciences (SPRB) details one-time executive stock option repricing - Stock Titan
Spruce Biosciences (SPRB) discloses CEO stock option repricing to $104.13 - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) details one-time director option repricing - Stock Titan
Spruce Biosciences (SPRB) details 800 stock options repriced for director - Stock Titan
Spruce Biosciences (SPRB) director receives 3,400 options at $88.41 - Stock Titan
[Form 3] SPRUCE BIOSCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directo - PharmiWeb.com
Spruce Biosciences appoints Keli Walbert to board of directors By Investing.com - Investing.com Australia
Spruce Biosciences appoints Keli Walbert to board of directors - marketscreener.com
Spruce Biosciences Appoints Keli Walbert To Board Of Directors - TradingView — Track All Markets
Spruce Biosciences (NASDAQ: SPRB) names rare-disease veteran Keli Walbert to board - Stock Titan
Spruce Biosciences (SPRB) adds Keli Walbert to board with cash and equity pay - Stock Titan
CEO Szwarcberg Acquires 3,524 Of Spruce Biosciences Inc [SPRB] - TradingView — Track All Markets
[8-K] SPRUCE BIOSCIENCES, INC. Reports Material Event | SPRB SEC FilingForm 8-K - Stock Titan
Spruce Biosciences (SPRB) insider RSU vesting and tax share withholding - Stock Titan
Stock Ratings | Guggenheim maintained its "buy" recommendation on Cybin Inc. Common Shares (CYBN) and raised its price target to $48 from $39, representing a potential upside of 378.12%. - Sahm
Spruce Biosciences (SPRB) price target increased by 55.76% to 213.69 - MSN
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - MarketBeat
Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Leerink Partners Upgrades Spruce Biosciences (SPRB) - Nasdaq
Spruce Biosciences Shares Rise After Upgrade From Leerink - marketscreener.com
SPRB: Leerink Partners Upgrades to Outperform with $160 Target | - GuruFocus
Leerink Partners upgrades Spruce Biosciences stock to Outperform By Investing.com - Investing.com Canada
Leerink Partners upgrades Spruce Biosciences stock to Outperform - Investing.com
Pharma execs reflect on 2025 - Healthcare Brew
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Spruce Biosciences Inc. (SPRB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Is Spruce Biosciences Stock Built to Withstand More Downside? - Trefis
Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock - MarketBeat
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):